IPO - Clene Inc.

Form Type: S-3

Filing Date: 2025-01-24

Corporate Action: Ipo

Type: New

Accession Number: 000143774925001794

Filing Summary: Clene Inc. filed a Registration Statement on Form S-3 with the SEC on January 24, 2025, to register up to 1,146,789 shares of its common stock under a shelf registration process. These shares are intended to be offered and resold by Selling Securityholders, including Kensington Clene 2024 LLC, 4Life Research, LLC, and La Scala Investments, LLC, as part of a note purchase agreement. The filing indicates that the common stock may also include additional shares to prevent dilution from stock splits or other similar transactions. Clene is a clinical-stage pharmaceutical company focused on developing novel therapeutics aimed at treating neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. Significant recent developments include receiving FDA guidance on an accelerated approval pathway for its lead drug candidate, CNM-Au8, in ALS. Clene reported continued financial challenges, with substantial losses and a growing accumulated deficit, emphasizing the need for additional funding to sustain operations. The company's common stock and public warrants are listed on the Nasdaq Capital Market under the symbols 'CLNN' and 'CLNNW,' respectively. A detailed exploration of clinical programs, market data, risk factors, and future plans are included in the prospectus, along with important legal disclaimers regarding forward-looking statements.

Document Link: View Document